Distinct autoantibody profiles across checkpoint inhibitor types and toxicities

Immune checkpoint inhibitors (ICI) are increasingly used in combination. To understand the effects of different ICI categories, we characterized changes in circulating autoantibodies in patients enrolled in the E4412 trial (NCT01896999) of brentuximab vedotin (BV) plus ipilimumab, BV plus nivolumab,...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology 2024-12, Vol.13 (1), p.2351255-2351255
Main Authors: Mu-Mosley, Hong, von Itzstein, Mitchell S., Fattah, Farjana, Liu, Jialiang, Zhu, Chengsong, Xie, Yang, Wakeland, Edward K., Park, Jason Y., Kahl, Brad S., Diefenbach, Catherine S., Gerber, David E.
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Autoantibodies
Autoantibodies - blood
Autoantibodies - immunology
biomarkers
Brentuximab Vedotin - therapeutic use
CTLA-4
Female
Hodgkin Disease - drug therapy
Hodgkin Disease - immunology
Humans
immune checkpoint inhibitor
Immune Checkpoint Inhibitors - administration & dosage
Immune Checkpoint Inhibitors - adverse effects
immune-related adverse events
immunotherapy
Ipilimumab - administration & dosage
Ipilimumab - adverse effects
Male
Middle Aged
Nivolumab - administration & dosage
Nivolumab - adverse effects
PD-1
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors (ICI) are increasingly used in combination. To understand the effects of different ICI categories, we characterized changes in circulating autoantibodies in patients enrolled in the E4412 trial (NCT01896999) of brentuximab vedotin (BV) plus ipilimumab, BV plus nivolumab, or BV plus ipilimumab-nivolumab for Hodgkin Lymphoma. Cycle 2 Day 1 (C2D1) autoantibody levels were compared to pre-treatment baseline. Across 112 autoantibodies tested, we generally observed increases in ipilimumab-containing regimens, with decreases noted in the nivolumab arm. Among 15 autoantibodies with significant changes at C2D1, all nivolumab cases exhibited decreases, with more than 90% of ipilimumab-exposed cases showing increases. Autoantibody profiles also showed differences according to immune-related adverse event (irAE) type, with rash generally featuring increases and liver toxicity demonstrating decreases. We conclude that dynamic autoantibody profiles may differ according to ICI category and irAE type. These findings may have relevance to clinical monitoring and irAE treatment.
ISSN:2162-402X
2162-402X
DOI:10.1080/2162402X.2024.2351255